CAPR vs SLDB
CAPR: Capricor is a clinical-stage biotech developing cell and exosome therapies for rare genetic disorders, with its lead candidate Deramiocel under FDA review for Duchenne muscular dystrophy treatment. SLDB: A gene therapy company advancing a pipeline of treatments for rare neuromuscular and cardiac diseases including Duchenne muscular dystrophy, Friedreich's ataxia, and cardiomyopathy.
Side-by-side fundamentals
| Metric | CAPR | SLDB | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $18.91 | $8.10 | |
| Market cap as of 2026-07-23 | $1.1B | $808M | |
| PEG as of 2026-07-23 | -0.14 | n/a | |
| Net margin as of 2026-07-23 | -181.7% | -588.3% | CAPR higher |
| Operating margin as of 2026-07-23 | -191.1% | -591.1% | CAPR higher |
| ROE as of 2026-07-23 | -59.3% | -74.5% | CAPR higher |
| ROA as of 2026-07-23 | -48.6% | -62.0% | CAPR higher |
| Debt / equity as of 2026-07-23 | 0.02 | 0.00 | SLDB lower |
| Beta as of 2026-07-23 | 0.37 | 2.40 | |
| 1-year return as of 2026-07-22 close | +190.0% | +32.8% | CAPR higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.